

Palladium Catalyzed Synthesis and Physical Properties of Indolo[2,3-*b*]quinoxalines

Tran Quang Hung,^a Do Huy Hoang,^{a,b} Ngo Ngoc Thang,^{a,b} Tuan Thanh Dang,^{a*} Khurshid Ayub,^c Alexander Villinger,^a Aleksej Friedrich,^d Stefan Lochbrunner,^d Gerd-Uwe Flechsig,^{a,e} Peter Langer^{a,b*}

^a Institut für Chemie, Universität Rostock, Albert-Einstein-Str. 3a, 18059 Rostock, Germany.

Fax: +49 381 4986412; Tel: +49 381 4986410

^b Leibniz Institut für Katalyse an der Universität Rostock e. V. (LIKAT), Albert-Einstein-Str. 29a, 18059 Rostock, Germany.

^c Department of Chemistry, COMSATS Institute of Information Technology, Abbottabad, Pakistan

^d Institut für Physik, Universität Rostock, Universitätsplatz 3, 18051 Rostock, Germany.

^e Division of Chemistry and Environmental Science, Manchester Metropolitan University, Chester Street, Manchester, M1 5GD, United Kingdom.

E-mail: peter.langer@uni-rostock.de; Email: thanhtuandang@hotmail.com

Supporting Information


Content List:

Experimental section: p. 2

Copies of NMR spectra : p. 19


Experimental Section

Synthesis of 2,3-dibromoquinoxaline



2,3-Dibromoquinoxaline was synthesized in 94% of overall yield using Li's procedure by reflux of 1,2-phenylenediamine with diethyl oxalate, to give 1,4-dihydroquinoxaline-2,3-dione, and subsequent reaction with PBr_5 .¹ M.p. 179-180 °C. ^1H NMR (300 MHz, CDCl_3) δ 8.08 – 8.01 (m, 2H), 7.86 – 7.78 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 141.42, 140.97, 131.49, 128.57; IR (ATR, cm^{-1}): ν = 3097 (m), 3034 (m), 1564 (m), 1549 (s), 1514 (s), 1479 (m), 1254 (s), 1169 (s), 1126 (m), 1107 (s), 1072 (m), 1059 (m), 957 (vs), 901 (m), 883 (m), 868 (s), 769 (vs), 692 (m), 677 (m), 621 (m), 582 (s); GC-MS (EI, 70 eV): m/z (%) = 288 (96), 209 (95), 128 (61), 102 (100), 75 (98), 50 (59); HRMS (EI): calcd. for $\text{C}_8\text{H}_4\text{N}_2\text{Br}_2$ ($[\text{M}]^+$): 285.87357; found: 285.87325; calcd. for $\text{C}_8\text{H}_4\text{N}_2\text{Br}_1^{81}\text{Br}_1$ ($[\text{M}]^+$): 287.87153; found: 287.87137; calcd. for $\text{C}_8\text{H}_4\text{N}_2^{81}\text{Br}_2$ ($[\text{M}]^+$): 289.86948; found: 289.86935.


General procedure for the preparation of 2-bromo-3-(2-bromophenyl)quinoxaline(9).



2,3-Dibromoquinoxaline **7** (1 g, 3.5 mmol), 2-bromophenyl boronic acid (837 mg, 4.2 mmol), $\text{Pd}(\text{PPh}_3)_4$ (100 mg, 87 μmol) and sodium hydroxide (417 mg, 10.4 mmol) were added to a 500 mL Schlenk flask. The mixture was back-filled several times with Argon. To the mixture 70 mL THF and 10 mL distilled water were added, then, back-filled several times. The reaction was heated at 70 °C for 4h. The solvent was evaporated *in vacuo*. The residue was extracted with


dichloromethane and water. The organic layer was dried over MgSO_4 , filtered and the solvent was evaporated *in vacuo*. The yellow residue was purified by column chromatography (silica gel, Heptane/ethylacetate 10:1) to yield 2-bromo-3-(2-bromophenyl)quinoxaline **9** (1.1 g, 87 %) as white solid. M.p. 127-129 °C; ^1H NMR (250 MHz, CDCl_3) δ 8.20 – 8.07 (m, 2H), 7.90 – 7.79 (m, 2H), 7.73 (dd, J = 7.9, 0.8 Hz, 1H), 7.55 – 7.35 (m, 3H); ^{13}C NMR (63 MHz, CDCl_3) δ 154.95, 142.47, 140.67, 140.11, 139.38, 132.99, 131.46, 131.01, 130.84, 130.49, 129.58, 128.57, 127.76, 122.83; IR (ATR, cm^{-1}): ν = 3059 (w), 1610 (w), 1556 (m), 1535 (w), 1477 (m), 1433 (m), 1385 (w), 1333 (m), 1290 (m), 1273 (w), 1252 (m), 1236 (w), 1213 (w), 1167 (w), 1147 (m), 1132 (m), 1084, 1041, 1024 (m), 999 (w), 970, 955 (m), 943 (m), 885 (m), 870 (w), 862 (w), 752 (vs), 727, 715, 710, 690 (m), 652 (m), 638 (m), 613 (m), 588, 571 (m), 557 (m); GC-MS (EI, 70 eV): m/z (%) = 364 (32), 285 (100), 102 (48), 75 (28), 50 (14); HRMS (EI): calcd. for $\text{C}_{14}\text{H}_8\text{N}_2\text{Br}_2$ ($[\text{M}]^+$): 361.90488; found: 361.90467; calcd. for $\text{C}_{14}\text{H}_8\text{N}_2\text{Br}_1^{81}\text{Br}_1$ ($[\text{M}]^+$): 363.90283; found: 363.90277; calcd. for $\text{C}_{14}\text{H}_8\text{N}_2^{81}\text{Br}_2$ ($[\text{M}]^+$): 365.90078; found: 365.90082.

General procedure A for double C-N coupling with aniline derivatives, exemplified by the synthesis of 6-phenyl-6H-indolo[2,3-b]quinoxaline (11a)




Aniline **10a** (75 μL , 0.82 mmol) was added to a pressure tube charged with **9** (100 mg, 0.28 mmol), $\text{Pd}_2(\text{dba})_3$ (12 mg, 14 μmol), ligand dppf (15 mg, 27 μmol) and sodium *tert*-butoxide (79 mg, 0.82 mmol) under Argon. The mixture was back-filled with Argon several times. The mixture was dissolved in anhydrous Toluene (10 mL) and heated at 100 °C for 7 h. After cooling, the reaction mixture was diluted with dichloromethane (20 mL) and filtered through a celite pad, washing with dichloromethane (40 mL). The filtrate was reduced *in vacuo*. The product was separated via flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield 6-phenyl-6H-

indolo[2,3-*b*]quinoxaline **11a** (67 mg, 83%) as a yellow solid; m.p. 238-239 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.56 (d, $J = 7.7$ Hz, 1H), 8.40 – 8.29 (m, 1H), 8.14 – 8.06 (m, 1H), 7.84 – 7.59 (m, 7H), 7.59 – 7.38 (m, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 146.00, 144.90, 140.72, 140.08, 139.69, 135.50, 131.25, 129.92, 129.24, 128.99, 128.38, 128.13, 127.27, 126.71, 122.94, 122.02, 119.83, 110.75; IR (ATR, cm^{-1}): $\nu = 3053$ (m), 1608 (m), 1597 (m), 1581 (m), 1500, 1483 (m), 1470 (m), 1458, 1402, 1390, 1354 (m), 1336 (m), 1317 (m), 1304 (m), 1252 (m), 1227 (m), 1205, 1174 (m), 1147 (m), 1132 (m), 1126 (m), 1099 (m), 1072 (m), 1041 (m), 1024 (m), 1014 (m), 1007 (m), 955 (m), 924 (m), 779 (m), 766 (m), 748 (vs), 719 (m), 694, 687, 648, 590, 567 (m); GC-MS (EI, 70 eV): m/z (%) = 295 (100), 147 (9), 90 (6), 77 (6); HRMS (ESI): calcd. for $\text{C}_{20}\text{H}_{14}\text{N}_3$ ($[\text{M} + \text{H}]^+$): 296.11822; found: 296.11835.




6-(*p*-Tolyl)-6H-indolo[2,3-*b*]quinoxaline 11b was prepared following general procedure A using compound **9** (100 mg, 0.28 mmol) and toluidine (88 mg, 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield **11b** (73 mg, 86%) as a yellow solid; m.p. 216-217 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.50 – 8.43 (m, 1H), 8.29 – 8.22 (m, 1H), 8.05 – 7.99 (m, 1H), 7.68 – 7.57 (m, 2H), 7.57 – 7.49 (m, 3H), 7.45 – 7.31 (m, 4H), 2.43 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 146.01, 144.99, 140.66, 140.06, 139.62, 138.04, 132.68, 131.06, 130.45, 129.17, 128.79, 128.27, 127.02, 126.46, 122.72, 121.73, 119.68, 110.62, 21.35; IR (ATR, cm^{-1}): $\nu = 3057$ (w), 3034 (w), 2918 (w), 1606 (m), 1585 (m), 1514, 1485 (m), 1470 (m), 1460, 1404, 1354 (m), 1335 (m), 1317, 1304 (m), 1255 (m), 1227 (m), 1221 (m), 1205, 1182 (m), 1169 (m), 1130 (m), 1122 (m), 1099 (m), 1043 (m), 1016 (m), 955 (m), 924 (m), 816 (m), 764, 750 (vs), 721 (m), 710 (m), 673 (w), 633 (m), 602, 579, 567 (m), 559 (m); GC-MS (EI, 70 eV): m/z (%) = 309 (100), 293 (8), 154 (7), 90 (5); HRMS (EI): calcd. for $\text{C}_{21}\text{H}_{15}\text{N}_3$ ($[\text{M}]^+$): 309.12605; found: 309.12523.



6-(4-Fluorophenyl)-6H-indolo[2,3-*b*]quinoxaline 11c was prepared following general procedure A using compound **9** (100 mg, 0.28 mmol) and 4-fluoroaniline (78 μL , 0.82 mmol). The product was


purified by flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield **11c** (69 mg, 80 %) as a yellow solid; m.p. 219-220 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.55 (d, J = 7.8 Hz, 1H), 8.37 – 8.30 (m, 1H), 8.12 – 8.04 (m, 1H), 7.78 – 7.61 (m, 5H), 7.50 – 7.41 (m, 2H), 7.41 – 7.30 (m, 2H); ^{19}F NMR (282 MHz, CDCl_3) δ -113.01; ^{13}C NMR (75 MHz, CDCl_3) δ 162.08 (d, J = 247.9 Hz), 146.07, 144.90, 140.70, 140.01 (d, J = 18.0 Hz), 131.43 (d, J = 3.2 Hz), 131.32, 129.38, 129.18 (d, J = 8.4 Hz), 129.12, 128.32, 126.81, 122.98, 122.15, 119.92, 116.99 (d, J = 22.9 Hz), 110.52; IR (ATR, cm^{-1}): ν = 3057 (m), 1608 (m), 1579 (m), 1574 (m), 1514, 1485, 1471 (m), 1460, 1402, 1356 (m), 1335 (m), 1313, 1292 (m), 1259 (m), 1223, 1203, 1171 (m), 1151 (m), 1130 (m), 1122, 1099, 1043 (m), 1012 (m), 1007 (m), 949 (m), 924 (m), 872 (m), 831, 812 (m), 800 (m), 764, 748 (vs), 723 (m), 710, 673 (m), 638 (m), 629 (m), 602, 579, 567 (m), 557 (m), 548 (m); GC-MS (EI, 70 eV): m/z (%) = 313 (100), 156 (12), 75 (7); HRMS (EI): calcd. for $\text{C}_{20}\text{H}_{12}\text{N}_3\text{F}_1$ ($[\text{M}]^+$): 313.10098; found: 313.10007.



6-(3-(Trifluoromethyl)phenyl)-6H-indolo[2,3-b]quinoxaline 11d


was prepared following general procedure A using compound **9** (100 mg, 0.28 mmol) and 3-(trifluoromethyl)aniline (103 μL , 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield **11d** (90 mg, 90 %) as a yellow solid; m.p. 201-202 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.46 (ddd, J = 7.7, 1.2, 0.7 Hz, 1H), 8.29 – 8.19 (m, 1H), 8.03 – 7.95 (m, 2H), 7.92 (ddd, J = 3.7, 3.0, 1.9 Hz, 1H), 7.76 – 7.53 (m, 5H), 7.48 – 7.33 (m, 2H); ^{19}F NMR (282 MHz, CDCl_3) δ -62.58; ^{13}C NMR (75 MHz, CDCl_3) δ 145.55, 144.00, 140.39, 140.07, 136.11, 132.31 (q, J = 33.0 Hz), 131.25, 130.40, 130.32, 130.31, 129.33, 129.11, 128.23, 126.90, 124.49 (q, J = 3.7 Hz), 123.85 (q, J = 3.9 Hz), 122.92, 123.74 (q, J = 272.5 Hz), 122.41, 120.16, 110.31; IR (ATR, cm^{-1}): ν = 3051 (w), 3028 (w), 1608 (w), 1597 (w), 1579 (w), 1574 (w), 1495 (m), 1464 (m), 1446 (m), 1406, 1356 (m), 1329, 1308 (m), 1279 (w), 1250 (m), 1230 (m), 1205 (m), 1167, 1134 (m), 1126 (m), 1113, 1105, 1095, 1068, 1045 (m), 1011 (m), 987 (w), 976 (w), 958 (m), 943 (m), 924 (w), 904 (m), 874 (w), 860 (w), 854 (w), 802 (m), 795 (m), 768 (m), 748 (vs), 719 (m), 700, 671, 656 (m), 631 (w), 615 (w), 588 (m), 567 (w), 546 (w); GC-MS (EI, 70 eV): m/z (%) = 363 (100), 294 (9);

HRMS (ESI): calcd. for $C_{21}H_{12}F_3N_3$ ($[M + H]^+$): 364.10561; found: 364.10566; calcd. for $C_{37}H_{37}N_5Na$ ($[M + Na]^+$): 574.29412; found: 574.2944.



6-(4-Methoxyphenyl)-6H-indolo[2,3-b]quinoxaline 11e was prepared following general procedure A using compound **9** (100 mg, 0.28 mmol) and p-anisidine (101 mg, 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 3:1) to yield **11e** (88 mg, 98 %) as a yellow solid; m.p. 226-228 °C; 1H NMR (300 MHz, $CDCl_3$) δ 8.57 (d, J = 7.6 Hz, 1H), 8.35 (d, J = 8.9


Hz, 1H), 8.15 – 8.05 (m, 1H), 7.80 – 7.55 (m, 5H), 7.44 (t, J = 8.3 Hz, 2H), 7.21 – 7.13 (m, 2H), 3.94 (s, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 159.42, 145.47, 140.85, 139.42, 131.35, 129.13, 129.00, 128.72, 128.38, 128.02, 126.67, 123.02, 121.87, 119.53, 115.27, 113.39, 110.68, 55.77; IR (ATR, cm^{-1}): ν = 3076 (w), 3053 (m), 3022 (m), 2956 (m), 2933 (m), 2912 (m), 2839 (m), 1606 (m), 1585 (m), 1578 (m), 1512, 1506, 1487 (m), 1464, 1446, 1406, 1356 (m), 1336 (m), 1313 (m), 1296, 1244, 1230, 1205, 1178, 1167, 1136, 1128, 1103, 1041 (m), 1026, 1009 (m), 968 (m), 955 (m), 939 (m), 924 (m), 870 (m), 852 (m), 829, 820, 804 (m), 795 (m), 768, 748 (vs), 723, 715, 669 (m), 642 (m), 629 (m), 602, 579, 569, 550; GC-MS (EI, 70 eV): m/z (%) = 325 (100), 310 (39), 282 (18), 141 (8); HRMS (ESI): calcd. for $C_{21}H_{15}N_3O$ ($[M + H]^+$): 326.12879; found: 326.12858.




6-(3,5-Dimethoxyphenyl)-6H-indolo[2,3-b]quinoxaline 11f was prepared following general procedure A using compound **9** (100 mg, 0.28 mmol) and 3,5-dimethoxyaniline (126 mg, 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 2:1) to yield **11f** (93 mg, 95 %) as a yellow solid; m.p. 188-189 °C; 1H NMR (300 MHz, $CDCl_3$) δ 8.45 (d, J =

7.6 Hz, 1H), 8.28 – 8.20 (m, 1H), 8.07 – 8.00 (m, 1H), 7.71 – 7.47 (m, 4H), 7.35 (ddd, J = 8.1, 6.9, 1.3 Hz, 1H), 6.81 (d, J = 2.3 Hz, 2H), 6.54 (t, J = 2.3 Hz, 1H), 3.79 (s, 6H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 161.59, 145.81, 144.67, 140.60, 140.16, 139.77, 136.91, 131.08, 129.25, 128.83, 128.35, 126.55, 122.66, 121.86, 119.84, 110.92, 105.51, 100.33, 55.66; IR (ATR, cm^{-1}): ν = 2993 (w), 2956 (w), 2926 (w), 1606 (m), 1591 (m), 1508 (w), 1491 (m), 1458, 1427 (m), 1404 (m),

1363 (w), 1325 (m), 1298 (m), 1257 (m), 1242 (m), 1207 (m), 1194, 1153, 1134 (m), 1124 (m), 1107 (m), 1066 (m), 1051 (m), 1039 (m), 1014 (m), 1003 (m), 993 (m), 953 (m), 933 (m), 912 (m), 877 (m), 860 (m), 847, 818 (m), 791 (m), 768, 735 (vs), 721, 688, 667 (m), 640 (m), 631 (m), 617 (m), 607 (m), 600 (m), 584, 577 (m), 565 (m), 534 (m); GC-MS (EI, 70 eV): m/z (%) = 355 (100), 325 (13), 268 (12); HRMS (EI): calcd. for C₂₂H₁₇O₂N₃ ([M]⁺): 355.13153; found: 355.13066.




6-(4-(Methylthio)phenyl)-6H-indolo[2,3-b]quinoxaline 11g was prepared following general procedure A using compound **9** (100 mg, 0.28 mmol) and 4-(methylthio)aniline (103 μ L, 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 3:1) to yield **11g** (88 mg, 94 %) as a white solid; m.p. 249-250°C; ¹H NMR (300 MHz, CDCl₃) δ 8.47 (d, *J* = 7.4 Hz, 1H), 8.28 – 8.20 (m, 1H), 8.06 – 7.98 (m, 1H), 7.72 – 7.53 (m, 5H), 7.51 – 7.30 (m, 4H), 2.53 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 145.88, 144.73, 140.58, 140.17, 139.82, 138.69, 132.30, 131.09, 129.28, 128.89, 128.23, 127.62, 127.52, 126.56, 122.73, 121.91, 119.85, 110.56, 15.92; IR (ATR, cm⁻¹): ν = 2955 (m), 2920, 2850 (m), 1608 (m), 1579 (m), 1498, 1483 (m), 1460, 1431 (m), 1402, 1352 (m), 1335 (m), 1311, 1296 (m), 1252 (m), 1230 (m), 1203, 1184 (m), 1132 (m), 1124 (m), 1115 (m), 1103, 1090, 1041 (m), 1012 (m), 1003 (m), 984 (m), 970 (m), 955 (m), 937 (m), 922 (m), 904 (w), 870 (m), 854 (w), 833 (m), 816, 768 (vs), 748 (vs), 719, 702, 661 (m), 634 (m), 625 (m), 590, 567, 548 (m); GC-MS (EI, 70 eV): m/z (%) = 341 (100), 326 (36), 294 (20), 102 (6); HRMS (ESI): calcd. for C₂₄H₂₂N₄ ([M + H]⁺): 367.19172; found: 367.19173.



5,7-Bis(4-(N,N-diethylamino)phenyl)-6H-indolo[2,3-b]quinoxaline 11h was prepared following general procedure A using compound **9** (100 mg, 0.28 mmol) and N¹,N¹-diethylbenzene-1,4-diamine (137 μ L, 0.82 mmol). The product was purified by flash chromatography (silica gel, Heptane/ethylacetate 3:1) to yield **11h** (76 mg, 75 %) as a yellow solid; m.p. 228-229 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.50 –


8.39 (m, 1H), 8.26 – 8.19 (m, 1H), 8.05 – 8.00 (m, 1H), 7.70 – 7.50 (m, 3H), 7.45 – 7.27 (m, 4H), 6.84 – 6.73 (m, 2H), 3.37 (q, $J = 7.1$ Hz, 4H), 1.17 (t, $J = 7.1$ Hz, 6H); ^{13}C NMR (75 MHz, CDCl_3) δ 147.61, 146.39, 145.80, 140.82, 140.23, 139.58, 130.90, 129.22, 128.57, 128.39, 128.29, 126.09, 122.55, 122.47, 121.29, 119.45, 112.09, 110.74, 44.55, 12.69; IR (ATR, cm^{-1}): ν = 2970 (w), 2926 (w), 2866 (w), 1626 (w), 1608 (m), 1578 (w), 1522, 1489 (m), 1462 (m), 1446 (m), 1429 (w), 1404 (m), 1371 (m), 1352 (m), 1333 (m), 1315 (m), 1279 (m), 1259 (m), 1228 (m), 1203, 1194, 1169 (m), 1157 (m), 1149 (m), 1134 (m), 1122 (m), 1101 (m), 1080 (m), 1041 (m), 1014 (m), 1003 (m), 978 (m), 953 (m), 924 (m), 864 (m), 849 (m), 814, 798, 758, 735 (vs), 723, 712, 667 (m), 640 (m), 631 (m), 596, 575, 563 (m), 548 (m), 532 (m); GC-MS (EI, 70 eV): m/z (%) = 366 (67), 351 (100), 322 (28), 294 (14), 243 (35), 194 (13), 165 (22); HRMS (ESI): calcd. for $\text{C}_{24}\text{H}_{22}\text{N}_4$ ($[\text{M} + \text{H}]^+$): 367.18780; found: 367.19184.




5,7-Bis(4-cyanophenyl)-6H-indolo[2,3-b]quinoxaline 11i was prepared following general procedure A using compound **9** (100 mg, 0.28 mmol) and 4-aminobenzonitrile (97 mg, 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 3:1) to yield **11i** (73 mg, 83 %) as a yellow solid; m.p. 272-273 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.47 (d, $J = 7.7$

Hz, 1H), 8.28 – 8.21 (m, 1H), 8.03 – 7.97 (m, 1H), 7.96 – 7.85 (m, 4H), 7.74 – 7.51 (m, 4H), 7.46 – 7.38 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 145.27, 143.33, 140.25, 140.17, 140.11, 139.68, 133.65, 131.31, 129.34, 129.32, 128.20, 127.20, 127.02, 123.06, 122.85, 120.49, 118.40, 110.91, 110.52; IR (ATR, cm^{-1}): ν = 2922 (m), 2852 (m), 2227 (m), 1601 (s), 1583 (m), 1506 (s), 1485 (m), 1456 (s), 1400 (s), 1354 (m), 1319 (s), 1304 (m), 1257 (m), 1238 (m), 1228 (m), 1219 (m), 1198 (s), 1169 (m), 1151 (m), 1136 (m), 1124 (s), 1103 (s), 1043 (m), 1014 (m), 955 (m), 949 (m), 922 (m), 837 (s), 823 (m), 769 (m), 758 (s), 746 (vs), 725 (m), 715 (m), 698 (m), 669 (m), 631 (m), 598 (s), 571 (m), 555 (s), 538 (s); GC-MS (EI, 70 eV): m/z (%) = 320 (100), 160 (9), 102 (7); HRMS (EI): calcd. for $\text{C}_{21}\text{H}_{12}\text{N}_4$ ($[\text{M}]^+$): 320.10565; found: 320.10491.

General procedure B for double C-N coupling with chain amine derivatives, exemplified by 6-propyl-6H-indolo[2,3-b]quinoxaline **11j**




To a pressure tube charged with **9** (100 mg, 0.28 mmol), Pd₂(dba)₃ (13 mg, 14 μmol), ligand DPEPhos (15 mg, 27 μmol) and sodium tert-butoxide (79 mg, 0.82 mmol) under Argon. The mixture was back-filled with Argon several times. The mixture was dissolved in anhydrous toluene (10 mL). n-propylamine (68 μL, 0.82 mmol) was added to the mixture and heated at 100 °C for 7 h. After cooling, the reaction mixture was diluted with dichloromethane (20 mL) and filtered through a celite pad, washing with dichloromethane (40 mL). The filtrate was reduced *in vacuo*. The product was separated via flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield **11j** (69 mg, 80%) as a yellow solid; m.p. 99-100 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.50 (d, *J* = 7.7 Hz, 1H), 8.31 (dd, *J* = 8.3, 1.3 Hz, 1H), 8.14 (dd, *J* = 8.3, 1.1 Hz, 1H), 7.82 – 7.60 (m, 3H), 7.48 (d, *J* = 8.2 Hz, 1H), 7.44 – 7.33 (m, 1H), 4.58 – 4.37 (m, 2H), 2.13 – 1.90 (m, 2H), 1.03 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (63 MHz, CDCl₃) δ 145.88, 144.70, 140.80, 140.09, 139.28, 131.08, 129.41, 128.84, 127.94, 126.05, 122.94, 120.90, 119.54, 109.68, 43.21, 21.96, 11.75; IR (ATR, cm⁻¹): ν = 3057 (w), 2970 (m), 2951 (m), 2929 (w), 2870 (m), 1610 (m), 1581 (m), 1574 (m), 1487 (s), 1464 (s), 1435 (m), 1406 (s), 1394 (m), 1369 (m), 1358 (s), 1348 (s), 1321 (s), 1294 (m), 1265 (w), 1257 (m), 1242 (m), 1232 (m), 1203 (s), 1182 (m), 1155 (m), 1113 (s), 1070 (m), 1034 (w), 1014 (m), 1003 (m), 951 (w), 939 (m), 893 (m), 883 (w), 870 (m), 850 (m), 768 (m), 746 (vs), 727 (s), 698 (s), 642 (m), 617 (m), 586 (s), 569 (m), 534 (m); GC-MS (EI, 70 eV): *m/z* (%) = 261 (46), 232 (73), 219 (100), 102 (11), 90 (10), 77 (7); HRMS (ESI): calcd. for C₁₇H₁₆N₃ ([M + H]⁺): 262.13387; found: 262.13391.



6-Pentyl-6H-indolo[2,3-b]quinoxaline 11k was prepared following general procedure B using compound **9** (100 mg, 0.28mmol) and n-pentylamine (96 μ L, 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield **11k** (74 mg, 93 %) as a yellow solid; m.p. 90-91 $^{\circ}$ C; ^1H NMR (300 MHz, CDCl_3) δ 8.40 (d, J = 7.6 Hz, 1H), 8.22 (dd, J = 8.3, 1.3 Hz, 1H),


8.06 (dd, J = 8.3, 1.2 Hz, 1H), 7.73 – 7.53 (m, 3H), 7.39 (d, J = 8.2 Hz, 1H), 7.35 – 7.25 (m, 1H), 4.45 – 4.34 (m, 2H), 1.94 – 1.77 (m, 2H), 1.33 (m, 4H), 0.81 (t, J = 7.1 Hz, 3H); ^{13}C NMR (63 MHz, CDCl_3) δ 145.65, 144.46, 140.66, 140.03, 139.23, 130.87, 129.31, 128.63, 127.82, 125.83, 122.72, 120.69, 119.47, 109.48, 41.44, 29.16, 28.15, 22.39, 13.94; IR (ATR, cm^{-1}): ν = 2964 (w), 2953 (w), 2931 (w), 2870 (w), 1608 (m), 1579 (m), 1491 (m), 1466 (s), 1441 (w), 1406 (s), 1379 (m), 1358 (m), 1323 (m), 1304 (m), 1246 (s), 1234 (m), 1200 (s), 1163 (m), 1153 (m), 1130 (m), 1115 (s), 1070 (m), 1051 (w), 1036 (w), 1014 (m), 1003 (m), 976 (w), 945 (w), 928 (m), 897 (w), 872 (w), 860 (w), 850 (m), 837 (w), 764 (s), 752 (s), 742 (vs), 729 (s), 717 (s), 692 (s), 665 (m), 640 (m), 629 (w), 613 (m), 606 (m), 586 (s), 571 (s), 555 (m), 534 (m); GC-MS (EI, 70 eV): m/z (%) = 289 (52), 260 (6), 246 (11), 2332 (80), 219 (100), 129 (11), 90 (10), 77 (9); HRMS (EI): calcd. for $\text{C}_{19}\text{H}_{19}\text{N}_3$ ($[\text{M}]^+$): 289.15735; found: 289.15720.




6-Heptyl-6H-indolo[2,3-b]quinoxaline 11j was prepared following general procedure B using compound **9** (100 mg, 0.28mmol) and n-heptylamine (122 μ L, 0.82mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield **11j** (74 mg, 85 %) as a yellow solid; m.p. 66-68 $^{\circ}$ C; ^1H NMR (300 MHz, CDCl_3) δ 8.50 (d, J =

7.7 Hz, 1H), 8.32 (dd, J = 8.3, 1.3 Hz, 1H), 8.15 (dd, J = 8.3, 1.2 Hz, 1H), 7.81 – 7.64 (m, 3H), 7.47 (d, J = 8.2 Hz, 1H), 7.42 – 7.32 (m, 1H), 4.58 – 4.40 (m, 2H), 2.03 – 1.85 (m, 2H), 1.51 – 1.16 (m, 8H), 0.86 (t, J = 6.8 Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 145.81, 144.67, 140.78, 139.89, 139.05, 131.16, 129.26, 128.86, 127.95, 126.10, 123.05, 120.92, 119.43, 109.67, 41.63, 31.85, 29.11, 28.60, 27.16, 22.73, 14.18; IR (ATR, cm^{-1}): ν = 2951 (m), 2922 (m), 2870 (m), 2850 (m), 1606 (m), 1581 (m), 1487 (s), 1464 (s), 1435 (m), 1408 (s), 1394 (m), 1369 (s), 1358

(s), 1346 (m), 1321 (s), 1304 (m), 1250 (m), 1240 (m), 1232 (m), 1203 (m), 1188 (m), 1176 (m), 1161 (m), 1149 (m), 1113 (s), 1070 (m), 1014 (m), 999 (m), 945 (m), 764 (s), 748 (vs), 721 (s), 698 (s), 642 (m), 615 (m), 586 (s), 569 (m), 534 (m); GC-MS (EI, 70 eV): m/z (%) = 317 (41), 233 (100), 219 (96), 102 (6); HRMS (ESI): calcd. for $C_{21}H_{24}N_3$ ($[M + H]^+$): 318.19647; found: 318.19666.




6-(Prop-1-en-1-yl)-6H-indolo[2,3-b]quinoxaline 11m was prepared following general procedure B using compound **9** (100 mg, 0.28mmol) and allylamine (62 μ L, 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield **11m** (52 mg, 73 %) as a yellow solid; m.p. 142-143 $^{\circ}$ C; 1H NMR (300 MHz, $CDCl_3$) δ 8.50 (d, J = 7.6 Hz, 1H), 8.32 (dd, J = 8.2, 1.4 Hz, 1H), 8.17 (dt, J = 12.4, 6.4 Hz, 1H), 7.83 – 7.63 (m, 3H), 7.42 (ddd, J = 10.8, 9.2, 8.0 Hz, 2H), 6.92 – 6.79 (m, 1H), 6.27 – 6.07 (m, 1H), 1.76 (dd, J = 7.0, 1.8 Hz, 3H); ^{13}C NMR (63 MHz, $CDCl_3$) δ 144.21, 140.60, 140.21, 139.48, 131.09, 129.27, 128.90, 128.23, 128.10, 126.42, 122.66, 121.60, 121.15, 119.85, 110.89, 14.18; IR (ATR, cm^{-1}): ν = 3055 (m), 3045 (m), 2978 (m), 2931 (m), 2912 (m), 2852 (m), 1662 (m), 1628 (m), 1606 (m), 1581 (m), 1574 (m), 1485 (s), 1462 (s), 1435 (m), 1427 (m), 1408 (vs), 1392 (s), 1358 (m), 1348 (m), 1335 (m), 1315 (s), 1265 (m), 1254 (s), 1234 (m), 1225 (m), 1209 (s), 1201 (s), 1178 (m), 1149 (m), 1138 (m), 1117 (s), 1093 (s), 1059 (m), 1034 (m), 1024 (m), 1016 (m), 1003 (m), 974 (m), 951 (m), 918 (m), 766 (s), 758 (s), 746 (vs), 735 (vs), 714 (s), 640 (m), 627 (s), 596 (s), 569 (m), 557 (m), 536 (s); GC-MS (EI, 70 eV): m/z (%) = 259 (100, 244 (29), 232 (22), 219 (42); HRMS (ESI): calcd. for $C_{17}H_{14}N_3$ ($[M + H]^+$): 260.11822; found: 260.11817.




6-Benzyl-6H-indolo[2,3-b]quinoxaline 11n was prepared following general procedure B using compound **9** (100 mg, 0.28 mmol) and benzylamine (90 μ L, 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 4:1) to yield **11n** (80 mg, 94 %) as a yellow solid; m.p. 181-182 $^{\circ}$ C; 1H NMR (300 MHz, $CDCl_3$) δ 8.42 (d, J = 7.5 Hz, 1H), 8.25 (dd, J = 8.2, 1.3 Hz, 1H), 8.06 (dd, J = 8.3, 1.2 Hz, 1H), 7.65 (dtd, J = 16.6, 6.9, 1.5 Hz, 2H), 7.57 – 7.47 (m, 1H), 7.36 – 7.08 (m, 7H), 5.63 (s,


^2H); ^{13}C NMR (75 MHz, CDCl_3) δ 145.96, 144.44, 140.81, 140.01, 139.50, 136.62, 131.21, 129.38, 128.99, 128.94, 128.04, 127.82, 127.34, 126.32, 122.95, 121.32, 119.72, 110.29, 45.16; IR (ATR, cm^{-1}): ν = 3059 (m), 3026 (w), 1610 (m), 1581 (m), 1574 (m), 1485 (s), 1466 (s), 1452 (m), 1433 (m), 1406 (s), 1394 (s), 1358 (m), 1346 (s), 1321 (s), 1306 (m), 1269 (m), 1259 (m), 1234 (m), 1196 (s), 1151 (m), 1134 (m), 1126 (m), 1113 (s), 1078 (m), 1066 (m), 1034 (m), 1026 (m), 1016 (m), 1007 (m), 985 (m), 918 (m), 895 (m), 854 (m), 766 (s), 746 (vs), 725 (s), 700 (vs), 685 (s), 650 (m), 615 (m), 592 (s), 575 (s), 555 (m), 534 (m); GC-MS (EI, 70 eV): m/z (%) = 309 (100), 266 (7), 251 (7), 232 (14), 207 (7), 91 (43), 84 (17), 66 (15), 49 (8); HRMS (ESI): calcd. for $\text{C}_{21}\text{H}_{16}\text{N}_3$ ($[\text{M} + \text{H}]^+$): 310.13387; found: 310.13398; calcd. for $\text{C}_{21}\text{H}_{16}\text{N}_3\text{Na}$ ($[\text{M} + \text{Na}]^+$): 332.11582; found: 332.11606.



6-(4-Methoxybenzyl)-6H-indolo[2,3-b]quinoxaline 11o was prepared following general procedure B using compound **9** (100 mg, 0.28 mmol) and 4-methoxybenzylamine (108 μL , 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 2:1) to yield **11o** (86 mg, 92 %) as a yellow solid; m.p. 129-130 $^\circ\text{C}$; ^1H NMR (300 MHz, CDCl_3) δ 8.40 (d, J = 7.2 Hz, 1H), 8.23 (dd, J = 8.2, 1.3 Hz, 1H), 8.07 (dd, J = 8.4, 1.1 Hz, 1H), 7.81 – 7.47 (m, 3H), 7.45 – 7.00 (m, 7H), 4.46 (t, J = 7.2 Hz, 2H), 2.84 – 2.57 (m, 2H), 2.24 (dt, J = 14.7, 7.5 Hz, 2H); ^{13}C NMR (63 MHz, CDCl_3) δ 145.68, 144.33, 141.01, 140.61, 140.01, 139.25, 130.92, 129.31, 128.72, 128.39, 128.35, 127.79, 126.06, 125.94, 122.77, 120.82, 119.51, 109.44, 41.01, 33.21, 29.73; IR (ATR, cm^{-1}): ν = 2929 (w), 1612 (w), 1583 (m), 1489 (m), 1470 (m), 1443 (w), 1410 (m), 1369 (m), 1360 (m), 1350 (m), 1325 (m), 1308 (w), 1282 (w), 1267 (w), 1244 (w), 1232 (w), 1207 (m), 1174 (m), 1161 (w), 1140 (w), 1128 (w), 1115 (m), 1088 (w), 1076 (w), 1070 (w), 1039 (w), 1032 (w), 1016 (w), 1005 (w), 987 (w), 976 (w), 951 (w), 935 (w), 928 (w), 758 (m), 737 (vs), 721 (m), 702 (s), 679 (m), 636 (w), 629 (w), 606 (m), 594 (m), 577 (m), 565 (m), 546 (w), 532 (m); GC-MS (EI, 70 eV): m/z (%) = 339 (37), 121 (100), 90 (12); HRMS (ESI): calcd. for $\text{C}_{22}\text{H}_{17}\text{N}_3\text{O}_1$ ($[\text{M} + \text{H}]^+$): 340.14444; found: 340.14427.




6-(4-Fluorobenzyl)-6H-indolo[2,3-b]quinoxaline 11p was prepared following general procedure B using compound **9** (100 mg, 0.28 mmol) and 4-fluorobenzylamine (94 μ L, 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ ethylacetate 4:1) to yield **11p** (78 mg, 87 %) as a yellow solid; m.p. 176-177 $^{\circ}$ C; ^1H NMR (300 MHz, CDCl_3) δ 8.40 (d, J = 7.7 Hz, 1H), 8.24 (dd, J = 8.3, 1.5 Hz, 1H), 8.05 (dd, J = 8.4, 1.3 Hz, 1H), 7.72 – 7.48 (m, 3H), 7.26 (ddd, J = 7.5, 6.8, 1.3 Hz, 4H), 6.94 – 6.83 (m, 2H), 5.57 (s, 2H); ^{19}F NMR (282 MHz, CDCl_3) δ -114.59; ^{13}C NMR (75 MHz, CDCl_3) δ 162.30 (d, J = 246.1 Hz), 145.70, 144.08, 140.63, 140.01, 139.59, 132.30 (d, J = 3.2 Hz), 131.05, 129.39, 129.00 (d, J = 8.2 Hz), 128.92, 127.88, 126.23, 122.82, 121.29, 119.74, 115.74 (d, J = 21.6 Hz), 109.97, 44.36; IR (ATR, cm^{-1}): ν = 3057 (w), 3045 (w), 1632 (w), 1610 (m), 1581 (m), 1508 (s), 1489 (m), 1468 (s), 1443 (w), 1435 (w), 1406 (s), 1363 (m), 1344 (m), 1325 (m), 1309 (w), 1300 (w), 1267 (w), 1240 (m), 1230 (w), 1217 (s), 1200 (s), 1171 (w), 1157 (m), 1140 (w), 1126 (w), 1117 (m), 1097 (m), 1066 (w), 1039 (w), 1016 (w), 1007 (w), 984 (w), 955 (w), 939 (w), 858 (m), 850 (m), 825 (m), 768 (m), 762 (s), 746 (vs), 729 (m), 721 (m), 712 (m), 690 (m), 640 (m), 631 (w), 617 (m), 592 (m), 571 (m), 557 (w), 534 (w); GC-MS (EI, 70 eV): m/z (%) = 327 (100), 232 (11), 218 (8), 109 (79), 90 (14); HRMS (EI): calcd. for $\text{C}_{21}\text{H}_{14}\text{N}_3\text{F}$ ($[\text{M}]^+$): 327.11663; found: 327.11625.




6-(3-(Trifluoromethyl)benzyl)-6H-indolo[2,3-b]quinoxaline 11q was prepared following general procedure B using compound **9** (100 mg, 0.28 mmol) and trifluoromethylbenzylamine (118 μ L, 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 4:1) to yield **11q** (87 mg, 84 %) as a yellow solid; m.p. 161-162 $^{\circ}$ C; ^1H NMR (300 MHz, CDCl_3) δ 8.44 – 8.38 (m, 1H), 8.28 – 8.21 (m, 1H), 8.07 – 8.01 (m, 1H), 7.72 – 7.40 (m, 5H), 7.40 – 7.19 (m, 4H), 5.65 (s, 2H); ^{19}F NMR (282 MHz, CDCl_3) δ -114.59; ^{13}C NMR (75 MHz, CDCl_3) δ 145.69, 143.97, 140.60, 139.99, 139.71, 137.63, 131.22 (q, J = 32.4 Hz), 131.15, 130.48, 129.43, 129.00, 127.89, 126.35, 124.68 (q, J = 3.7 Hz), 124.12 (q, J = 3.8 Hz), 123.93 (q, J = 272.4 Hz), 122.89, 121.48, 119.84, 109.79, 44.67; IR (ATR, cm^{-1}): ν = 3064 (w), 1612 (m), 1587 (m), 1489 (m), 1468 (s), 1452 (w),

1435 (w), 1410 (s), 1358 (w), 1338 (s), 1325 (s), 1275 (m), 1267 (w), 1244 (m), 1196 (s), 1163 (m), 1151 (s), 1111 (s), 1099 (vs), 1074 (s), 1043 (m), 1009 (m), 989 (m), 978 (w), 951 (w), 941 (w), 933 (w), 914 (m), 891 (w), 864 (w), 852 (w), 804 (m), 766 (m), 746 (vs), 729 (m), 721 (m), 704 (s), 698 (s), 675 (w), 661 (m), 648 (m), 629 (m), 607 (m), 600 (m), 592 (m), 575 (m), 552 (m), 534 (w); GC-MS (EI, 70 eV): m/z (%) = 377 (100), 232 (25), 218 (11), 159 (27), 90 (19); HRMS (EI): calcd. for $C_{22}H_{14}N_3F_3$ ($[M]^+$): 377.11343; found: 377.11287.




6-Phenethyl-6H-indolo[2,3-b]quinoxaline 11r was prepared following general procedure B using compound **9** (100 mg, 0.28 mmol) and phenylethylamine (104 μ L, 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield **11r** (79 mg, 89 %) as a yellow solid; m.p. 155-156 $^{\circ}$ C; 1H NMR (300 MHz, $CDCl_3$) δ 8.39 (d, J =

7.7 Hz, 1H), 8.23 (dd, J = 8.2, 1.3 Hz, 1H), 8.07 (dd, J = 8.4, 1.1 Hz, 1H), 7.74 – 7.49 (m, 3H), 7.35 – 7.04 (m, 7H), 4.69 – 4.56 (m, 2H), 3.22 – 3.09 (m, 2H); ^{13}C NMR (63 MHz, $CDCl_3$) δ 145.46, 144.32, 140.63, 140.05, 139.31, 138.46, 130.86, 129.31, 128.86, 128.69, 128.58, 127.86, 126.65, 125.97, 122.71, 120.80, 119.42, 109.35, 43.11, 34.74; IR (ATR, cm^{-1}): ν = 3055 (w), 2933 (w), 1610 (m), 1581 (m), 1487 (m), 1466 (s), 1439 (m), 1410 (s), 1394 (m), 1360 (m), 1344 (m), 1321 (m), 1286 (w), 1259 (w), 1244 (m), 1205 (m), 1184 (m), 1176 (m), 1151 (m), 1138 (m), 1117 (s), 1066 (m), 1039 (m), 1032 (m), 1014 (m), 999 (m), 982 (w), 947 (w), 930 (w), 868 (w), 766 (s), 756 (s), 742 (vs), 725 (m), 704 (s), 692 (s), 640 (m), 619 (w), 594 (s), 571 (m), 559 (m), 532 (m); GC-MS (EI, 70 eV): m/z (%) = 323 (16), 232 (100), 219 (61), 129 (10), 102 (10), 91 (9); HRMS (EI): calcd. for $C_{22}H_{17}N_3$ ($[M]^+$): 323.14170; found: 323.14153.




6-(3-Phenylpropyl)-6H-indolo[2,3-b]quinoxaline 11s was prepared following general procedure B using compound **9** (100 mg, 0.28 mmol) and phenylpropylamine (117 μ L, 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield **11s** (84 mg, 91 %) as a yellow

solid; m.p. 180-181 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.41 (d, J = 7.7 Hz, 1H), 8.25 (dd, J = 8.3, 1.3 Hz, 1H), 8.08 (dd, J = 8.3, 1.2 Hz, 1H), 7.77 – 7.49 (m, 3H), 7.36 – 7.19 (m, 4H), 6.78 – 6.71 (m, 2H), 5.58 (s, 2H), 3.67 (s, 3H); ^{13}C NMR (63 MHz, CDCl_3) δ 159.11, 145.77, 144.26, 140.67, 140.05, 139.47, 130.95, 129.33, 128.77, 128.62, 128.59, 127.88, 126.06, 122.69, 121.06, 119.66, 114.15, 110.14, 55.22, 44.49; IR (ATR, cm^{-1}): ν = 3055 (w), 2955 (w), 2931 (w), 2837 (w), 1610 (m), 1581 (m), 1514 (s), 1489 (m), 1466 (s), 1439 (m), 1423 (w), 1408 (s), 1398 (m), 1365 (m), 1344 (m), 1327 (m), 1304 (m), 1271 (m), 1246 (s), 1196 (s), 1184 (s), 1157 (w), 1142 (m), 1115 (s), 1066 (m), 1032 (s), 1005 (m), 984 (w), 953 (w), 933 (w), 858 (w), 835 (m), 820 (m), 802 (w), 762 (s), 742 (vs), 721 (m), 714 (m), 685 (s), 650 (m), 633 (m), 615 (m), 590 (s), 571 (m), 557 (w), 540 (m); GC-MS (EI, 70 eV): m/z (%) = 337 (35), 233 (100); HRMS (ESI): calcd. for $([\text{M} + \text{H}]^+)$: 338.16517; found: 338.16549; calcd. for $\text{C}_{23}\text{H}_{19}\text{N}_3\text{Na}$ $([\text{M} + \text{Na}]^+)$: 360.14712; found: 360.14751.




6-Cyclohexyl-6H-indolo[2,3-b]quinoxaline 11t was prepared following general procedure B using compound **9** (100 mg, 0.28 mmol) and cyclohexylamine (90 μL , 0.82 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield **11t** (61 mg, 74 %) as a yellow solid; m.p. 215-216 °C; ^1H NMR (250 MHz, CDCl_3) δ 8.52 (d, J = 7.7 Hz, 1H), 8.30 (dd, J = 8.2, 1.2 Hz, 1H), 8.15 (dd, J = 8.3, 1.2 Hz, 1H), 7.81 – 7.57 (m, 4H), 7.36 (ddd, J = 8.0, 4.8, 3.4 Hz, 1H), 4.97 (ddd, J = 12.4, 8.8, 3.8 Hz, 1H), 2.59 (tt, J = 12.4, 6.1 Hz, 2H), 2.23 – 0.59 (m, 8H); ^{13}C NMR (63 MHz, CDCl_3) δ 145.68, 144.03, 140.60, 140.05, 139.06, 130.76, 129.29, 128.70, 128.05, 126.02, 122.96, 120.53, 119.96, 111.27, 54.09, 30.38, 26.40, 25.71; IR (ATR, cm^{-1}): ν = 2931 (m), 2854 (m), 1608 (w), 1579 (m), 1574 (m), 1485 (m), 1460 (m), 1435 (w), 1404 (s), 1383 (m), 1346 (m), 1327 (m), 1321 (m), 1298 (m), 1263 (w), 1252 (w), 1234 (m), 1205 (s), 1124 (m), 1117 (s), 1090 (w), 1066 (m), 1043 (m), 1009 (m), 980 (w), 945 (m), 889 (m), 862 (w), 850 (w), 804 (w), 764 (m), 746 (vs), 717 (m), 696 (w), 638 (m), 592 (s), 569 (m), 540 (w); GC-MS (EI, 70 eV): m/z (%) = 301 (20), 219 (100); HRMS (EI): calcd. for $\text{C}_{20}\text{H}_{19}\text{N}_3$ $([\text{M}]^+)$: 301.15735; found: 301.15679.


General procedure C for C-N coupling/C-H bond activation, exemplified by: 6-phenyl-6H-indolo[2,3-b]quinoxaline 8a



To a pressure tube charged with 2,3-dibromoquinoxaline **7** (100 mg, 0.35 mmol), Pd(OAc)₂ (3 mg, 14 μmol), ligand PCy₃·HBF₄ (11 mg, 29 μmol) and sodium *tert*-butoxide (83 mg, 0.87mmol) under Argon. The mixture was back-filled with Argon several times. The mixture was dissolved in anhydrous Toluene (10 mL). Diphenylamine (49 mg, 0.29mmol) was added to the mixture and heated at 105 °C for 18 h. After cooling, the reaction mixture was diluted with dichloromethane (20 mL) and filtered through a celite pad, washing with dichloromethane (40 mL). The filtrate was reduced *in vacuo*. The product was separated via flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield **8a** (77 mg, 90%) as a yellow solid; m.p. 230-231°C; ¹H NMR (300 MHz, CDCl₃) δ 8.49 – 8.41 (m, 1H), 8.27 – 8.20 (m, 1H), 8.03 – 7.97 (m, 1H), 7.70 – 7.51 (m, 7H), 7.48 – 7.39 (m, 2H), 7.39 – 7.31 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 145.86, 144.74, 140.60, 140.18, 139.82, 135.43, 131.03, 129.80, 129.27, 128.83, 128.26, 127.99, 127.16, 126.51, 122.70, 121.86, 119.86, 110.62; IR (ATR, cm⁻¹): ν = 3054 (w), 1608 (w), 1597 (w), 1581 (m), 1571 (w), 1501 (m), 1483 (m), 1470 (m), 1458 (m), 1451 (m), 1403 (s), 1390 (m), 1354 (w), 1336 (w), 1318 (m), 1303 (m), 1252 (m), 1226 (m), 1219 (m), 1205 (s), 1174 (m), 1166 (m), 1133 (m), 1126 (m), 1100 (m), 1073 (w), 1042 (w), 1025 (w), 1015 (w), 1007 (w), 954 (w), 949 (w), 780 (m), 766 (m), 758 (m), 748 (vs), 719 (w), 694 (s), 687 (s), 649 (m), 590 (s), 485 (m), 451 (s), 428 (w); GC-MS (EI, 70 eV): m/z (%) = 295 (100), 147 (10); HRMS (EI): calcd. for C₂₀H₁₃N₃ ([M]⁺):295.11040; found: 295.10963.



6-Mesityl-9-methyl-6H-indolo[2,3-b]quinoxaline 8b was prepared following general procedure C using compound **7** (100 mg, 0.35 mmol) and 2,4,6-trimethyl-*N*-(*p*-tolyl)aniline (65 mg, 0.29 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 5:1) to yield **8b** (48 mg, 47 %) as a yellow solid; m.p.175-176 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.31 – 8.20 (m, 2H), 8.03 – 7.94 (m, 1H), 7.65 – 7.53 (m, 2H), 7.36 – 7.30 (m, 1H), 7.02 (s, 2H), 6.81 (d, J = 8.3 Hz, 1H), 2.48 (s, 3H), 2.33 (s, 3H), 1.82 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3) δ 145.80, 142.90, 141.03, 139.92, 139.52, 139.07, 137.45, 132.42, 131.04, 130.35, 129.65, 129.30, 128.58, 128.23, 126.08, 122.74, 119.66, 110.07, 21.30, 21.29, 17.88; IR (ATR, cm^{-1}): ν = 3019 (w), 2944 (w), 2913 (w), 2855 (w), 1609 (w), 1587 (w), 1577 (w), 1483 (s), 1471 (m), 1454 (m), 1441 (m), 1394 (m), 1386 (m), 1377 (m), 1361 (w), 1349 (m), 1326 (w), 1316 (m), 1303 (m), 1289 (m), 1251 (m), 1237 (m), 1206 (m), 1197 (m), 1179 (m), 1143 (w), 1130 (m), 1124 (m), 1112 (m), 1044 (m), 1032 (w), 1015 (w), 960 (w), 949 (w), 912 (m), 884 (m), 863 (w), 852 (m), 815 (w), 806 (s), 773 (w), 755 (vs), 749 (s), 728 (m), 719 (m), 678 (w), 670 (w), 656 (w), 642 (w), 630 (m), 603 (w), 596 (m), 586 (m), 571 (m), 565 (m), 549 (w), 540 (w), 522 (w), 516 (w), 512 (w), 508 (w), 498 (w), 485 (m), 472 (w), 449 (vs), 428 (m), 422 (m), 409 (w), 400 (w), 396 (w), 393 (w), 389 (w), 380 (w); GC-MS (EI, 70 eV): m/z (%) = 351 (100), 336 (20), 320 (7), 160 (11), 119 (7); HRMS (EI): calcd. for $\text{C}_{24}\text{H}_{21}\text{N}_3$ ($[\text{M}]^+$): 351.17300; found: 351.17195.




9-Methoxy-6-(4-methoxyphenyl)-6H-indolo[2,3-b]quinoxaline 8c was prepared following general procedure C using compound **7** (100 mg, 0.35 mmol) and bis(4-methoxyphenyl)amine (66 mg, 0.29 mmol). The product was purified by flash chromatography (silica gel, heptanes/ethylacetate 1:1) to yield **8c** (56 mg, 54 %) as a yellow solid; m.p.163-164 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.26 – 8.20 (m, 2H), 8.03 – 7.98 (m, 2H), 7.93 (d, J = 2.5 Hz, 2H), 7.62 (tt, J = 6.8, 5.1 Hz, 4H), 7.56 – 7.49 (m, 4H), 7.30 (d, J = 8.9 Hz, 2H), 7.17 (dd, J = 8.6, 2.9 Hz, 3H), 7.11 – 7.04 (m, 4H), 3.91 (s, 6H), 3.85 (s, 6H); ^{13}C NMR (63 MHz, CDCl_3) δ 159.05, 155.31, 146.25, 140.69, 139.95, 139.84, 139.43, 129.13, 128.70, 128.36, 128.20, 128.16, 126.24, 120.47, 119.88, 115.04,

111.51, 104.45, 56.12, 55.59; IR (ATR, cm^{-1}): ν = 3054 (w), 3017 (w), 2993 (w), 2837 (m), 1614 (w), 1572 (w), 1512 (s), 1487 (vs), 1473 (s), 1466 (s), 1458 (s), 1454 (s), 1438 (s), 1420 (m), 1395 (s), 1388 (s), 1293 (s), 1247 (s), 1197 (vs), 1185 (s), 1174 (vs), 1164 (s), 1138 (m), 1126 (s), 1107 (m), 1040 (s), 1031 (s), 1024 (s), 954 (m), 925 (m), 888 (m), 827 (vs), 809 (s), 802 (m), 793 (s), 764 (s), 756 (vs), 751 (s), 719 (m), 712 (m), 652 (m), 635 (m), 631 (m), 624 (m), 603 (s), 590 (s), 561 (m), 555 (m), 549 (m), 525 (m), 518 (m), 489 (m), 455 (s), 435 (m), 419 (m); GC-MS (EI, 70 eV): m/z (%) = 355 (100), 340 (76), 269 (12), 178 (7); HRMS (EI): calcd. for $\text{C}_{22}\text{H}_{17}\text{O}_2\text{N}_3$ ($[\text{M}]^+$): 355.13153; found: 355.13112.

References

- (1) Li, J. J.; Carson, K. G.; Trivedi, B. K.; Yue, W. S.; Ye, Q.; Glynn, R. a; Miller, S. R.; Connor, D. T.; Roth, B. D.; Luly, J. R.; Low, J. E.; Heilig, D. J.; Yang, W.; Qin, S.; Hunt, S. *Bioorg. Med. Chem.***2003**, *11*, 3777–3790.

121127.u320
Hung HT-2H144-2 1H CDCl3




f1 (ppm)

121127.u320
Hung 2H144-2 13C CDCl3

141.42
140.97



131.49
128.57

77.58
77.16
76.74






180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
f1 (ppm)


121127.u320
Hung 2H144-2 Dept CDCl3




130205.205
Hung HT-2H146b 1H CDCl3









130215.u306
Hung HT-2H181 1H CDCl3



130215.u306
Hung HT-2H181 13C CDCl3



146.00
144.90
140.72
140.08
139.69
135.50
131.25
129.92
129.24
128.99
128.38
128.13
127.27
126.71
122.94
122.02
119.83
110.75


77.58
77.16
76.74




130215.u306
Hung HT-2H181 Dept CDCl3

131.25
129.92
129.24
128.99
128.38
128.13
127.28
126.72
122.94
122.02
110.75









130426.u317
Hung HT-2H194 1H CDCl3




130426.u317
Hung HT-2H194 13C CDCl3



130426.u317
Hung HT-2H194 Dept CDCl3



130228.u308
Hung HT-2H195 1H CDCl3





130228.u308

Hung HT-2H195

19F

CDCl₃



130228.u308

Hung HT-2H195 13C CDCl3

163.72
160.43

146.07
144.90

140.70
140.13
139.89


131.32
129.23

129.12
128.32

126.81
122.98


122.15
117.14
116.83
116.52


77.58
77.16
76.74





200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0


f1 (ppm)








130828.u304
Hung HT-3H049 19F CDCl3







130215.u307
Hung HT-2H182 1H CDCl3





130215.u307
Hung HT-2H182 13C CDCl3


159.42
145.47
140.85
139.42
131.35
129.13
129.00
128.72
128.38
128.02
126.67
123.02
121.87
119.53
115.27
113.39
110.68

77.58
77.16
76.74



55.77



130215.u307
Hung HT-2H182 Dept CDCl3





130830.u338
Hung HT-3H048 1H CDCl3





f1 (ppm)



130830.u338
Hung HT-3H048 13C CDCl3




130830.u338
Hung HT-3H048 Dept CDCl3




130830.u316
Hung HT-3H044 1H CDCl3




130830.u316
Hung HT-3H044 13C CDCl3





130830.u316
Hung HT-3H044 Dept CDCl3








130830.u318
Hung HT-3H046 13C CDCl3





130830.u318
Hung HT-3H046 Dept CDCl3








130830.u317
Hung HT-3H045 13C CDCl3








130228.u309
Hung HT-2H196 1H CDCI3










130916.u313
Hung HT-50 1H CDCl3





130916.208
Hung HT-50 13C CDCl3









130218.u304
Hung HT-2H183 1H CDCl3





130218.u304
Hung HT-2H183 13C CDCl3





130218.u304
Hung HT-2H183
Dept CDCl3




130228.u310
Hung HT-2H197 1H CDCl3









130218.u305
Hung HT-2H184 1H CDCl3





130218.u305
Hung HT-2H184 13C CDCl3





130218.u305
Hung HT-2H184 Dept CDCl3




130927.u309
Hung HT-3H055 1H CDCl3





130927.206
Hung HT-3H055 13C CDCl3







130906.u325
Hung HT-52 1H CDCl3




131118.u320
Hung HT-3H052 19F CDCl3






130906.u325
Hung HT-52 Dept

CDCI3






131.05
129.40
129.06
128.95
128.92
127.88
126.23
122.82
121.29
115.88
115.59
109.97


44.36





130906.u324
Hung HT-51 1H CDCl3











130906.u324
Hung HT-51 Dept CDCl3





130927.u308
Hung HT-3H054 1H CDCl3





130927.205
Hung HT-3H054 13C CDCl3




130927.205
Hung HT-3H054 Dept CDCl3















130219.214
Hung HT-2H185 1H CDCl3




130219.214
Hung HT-2H185 13C CDCl3




130219.214
Hung HT-2H185 Dept CDCl3







140210.u325
Hung HT-3H075-2 137 CDCl3




- 145.86
- 144.74
- 140.60
- 140.18
- 139.82
- 135.43
- 131.03
- 129.80
- 129.27
- 128.83
- 128.26
- 127.99
- 127.16
- 126.51
- 122.70
- 121.86
- 119.86
- 110.62



140210.u325
Hung HT-3H075-2 Dept CDS13




131.03
129.80
129.27
128.83
128.26
127.99
127.16
126.51
122.70
121.86
110.62




140210.u326
Hung HT-3H077-2
CDCl₃

8.29
8.28
8.28
8.25
8.24
8.24
8.23
8.22
8.22
8.01
8.00
8.00
7.98
7.97
7.61
7.60
7.60
7.59
7.57
7.57
7.56
7.34
7.34
7.33
7.31
7.31
7.15
7.02
6.82
6.80





2.48
2.33
1.82




140210.u326
Hung HT-3H077-2 13C CDCl3

145.80
142.90
141.03
139.92
139.52
139.07
137.45
132.42
131.04
130.35
129.65
129.30
128.58
128.23
126.08
122.74
119.66
110.07

21.30
21.29
17.88




140210.u326
Hung HT-3H077-2 Dept CDCl3




140225.u325
Hung HT-3H0912

7.24 7.24 7.24 7.22 8.21 8.02 8.00 7.99 7.99 7.93 7.93 7.66 7.65 7.64 7.63 7.62 7.61 7.60 7.59 7.58 7.56 7.54 7.54 7.52 7.51 7.32 7.29 7.19 7.18 7.16 7.15 7.10 7.09 7.08 7.07 7.06



140225.227
Hung HT-3H091-2 13C CDCl3



140225.227
Hung HT-3H091-2 Dept CDCl3

